Scholarlink

<p>Metastatic breast cancer (BC) to the cervix is relatively rare among women with BC. Although the most common histopathological type of BC is invasive ductal carcinoma, invasive lobular carcinoma is more likely to metastasize to the female reproductive system due to its characteristic of the loss of E-cadherin. BC patients with metastasis to the cervix often exhibit no obvious clinical symptoms or may present with cervical-related symptoms, making early diagnosis challenging. CDK4/6 inhibitors, when combined with either aromatase inhibitors or fulvestrant, can enhance the prognosis for both premenopausal and postmenopausal women with recurrent ER-positive BC. We reported a patient with cervical metastasis of BC, who was ER-positive and HER2-negative. The patient received treatment with fulvestrant and abemaciclib after surgery for metastatic cervical cancer, achieving a progression-free survival of 31&#xa0;months. We hope this case report will encourage more clinicians to prioritize gynecological examinations for patients with BC, particularly cervical cancer screening, in order to enhance the quality of life and prognosis for these individuals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cervical metastasis of breast cancer: a case report and review of the literature

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月29日

查看全文
  • Yuping Shan,
  • Feng Hou,
  • Yan Wang,
  • Yi Han,
  • Zhumei Cui,
  • Guangjie Yin

摘要

Metastatic breast cancer (BC) to the cervix is relatively rare among women with BC. Although the most common histopathological type of BC is invasive ductal carcinoma, invasive lobular carcinoma is more likely to metastasize to the female reproductive system due to its characteristic of the loss of E-cadherin. BC patients with metastasis to the cervix often exhibit no obvious clinical symptoms or may present with cervical-related symptoms, making early diagnosis challenging. CDK4/6 inhibitors, when combined with either aromatase inhibitors or fulvestrant, can enhance the prognosis for both premenopausal and postmenopausal women with recurrent ER-positive BC. We reported a patient with cervical metastasis of BC, who was ER-positive and HER2-negative. The patient received treatment with fulvestrant and abemaciclib after surgery for metastatic cervical cancer, achieving a progression-free survival of 31 months. We hope this case report will encourage more clinicians to prioritize gynecological examinations for patients with BC, particularly cervical cancer screening, in order to enhance the quality of life and prognosis for these individuals.